Kenneth Baillie

Chief Executive Officer

Kenneth Baillie, FRSE FMedSci, is a visionary leader who bridges the gap between genomic discovery and clinical breakthroughs.

When every genomics group in the world was spending billions to solve the same problem, Baillie’s clinical and scientific insight put his team ahead: he was first to discover 75% of Covid-19 host genes. His genetics and computational biology work led directly to the discovery of baricitinib as an effective COVID-19 treatment - the first time in history that a host genetic discovery has led to an effective new drug treatment for any infectious disease.

He has secured over £100 million in career funding, is in the top 1% of highly-cited researchers worldwide. He is leveraging his unique expertise in genomics, biological systems, and medicine to lead Multiscale Labs to transform patients’ lives.